【4 月 28 日，新华制药传来新消息！】近日，新华制药收到国家药品监督管理局核准签发的甲钴胺片《药品补充申请批准通知书》，批准该药品上市许可持有人转让补充申请。按照相关规定，本次交易事项无需提交公司及股东大会审议，不构成关联交易和重大资产重组。甲钴胺片用于周围神经病，属医保乙类品种。据统计，2023 年中国公立医疗机构甲钴胺片销售额约 14.31 亿元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.